← Back to Clinical Trials
Recruiting NCT07445386

NCT07445386 Transdiscal vs Paravertebral Neurolytic Splanchnic Nerve Block for Upper Abdominal Cancer Pain

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07445386
Status Recruiting
Phase
Sponsor Ankara Etlik City Hospital
Condition Cancer Pain
Study Type INTERVENTIONAL
Enrollment 56 participants
Start Date 2026-02-16
Primary Completion 2026-08-16

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
transdiscal splanchnic neurolysisparavertebral splanchnic neurolysis

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 56 participants in total. It began in 2026-02-16 with a primary completion date of 2026-08-16.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare the efficacy of fluoroscopy-guided paravertebral (PV) and transdiscal (TD) approaches for splanchnic nerve neurolysis in patients with upper abdominal cancer-related pain (e.g., gastric, pancreatic, and hepatic malignancies). Treatment response will be assessed using the Numerical Rating Scale (NRS), and the impact of both techniques on quality of life will be evaluated with the EORTC QLQ-C30 questionnaire.

Eligibility Criteria

Inclusion Criteria: * Severe abdominal pain (NRS \> 6) due to upper intra-abdominal organ malignancies (such as gastric, pancreatic, or hepatic cancer). * Failure of pain control with conservative treatment modalities. Exclusion Criteria: * Presence of local anatomical variations * Localized or systemic infection involving the procedural site * Pregnancy * Coagulopathy * Presence of unstable psychiatric disorders

Contact & Investigator

Central Contact

Gokhan Yildiz

✉ gkoyldz@gmail.com

📞 5059272589

Principal Investigator

Gokhan Yildiz

PRINCIPAL INVESTIGATOR

Ankara Etlik City Hospital

Frequently Asked Questions

Who can join the NCT07445386 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07445386 currently recruiting?

Yes, NCT07445386 is actively recruiting participants. Contact the research team at gkoyldz@gmail.com for enrollment information.

Where is the NCT07445386 trial being conducted?

This trial is being conducted at Ankara, Turkey (Türkiye).

Who is sponsoring the NCT07445386 clinical trial?

NCT07445386 is sponsored by Ankara Etlik City Hospital. The principal investigator is Gokhan Yildiz at Ankara Etlik City Hospital. The trial plans to enroll 56 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology